Method of Participation
Participants should read the CE information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via e-mail or you may print it out at that time.
After completing this activity, participants should be better able to:
- Design optimal treatment strategies for patients with rheumatoid arthritis (RA) to improve remission rates and/or minimize levels of disease
- Recognize the role that Janus kinase (JAK) plays in the pathogenesis of RA and the corresponding impact of JAK inhibition in the management of RA
- Discuss treatment options for RA, including the use of JAK inhibitors, as reflected in current practice guidelines
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Global Academy of Medical Education. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.
This educational activity for 0.75 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Current guidelines for the management of rheumatoid arthritis (RA) address the concern that many patients fail to respond, or lose response, to first-line therapy with disease-modifying antirheumatic drugs (DMARDs). Lack of understanding about the optimal use of available RA therapies – including combination therapy or switching to other drugs within a class or in a different class – means that many patients may fail to achieve remission (the ideal goal) or minimal levels of disease activity. Clinicians who are unaware of current practice guidelines may not be providing optimal management of their patients with RA. In addition, clinicians should be aware of data concerning the safety and efficacy of newly available drugs so as to ensure selection of optimal therapies for patients with RA. Knowledge of agents that have novel mechanisms of action, including Janus kinase inhibitors, can improve clinicians’ confidence when switching therapies in patients who have suboptimal response despite appropriate use of DMARD therapies.
- Program Overview
- Suboptimal Outcomes in the Management of RA: Where Are We Failing Our Patients?
- A Comparison of Small Molecules and Biologics in the Management of RA
- The Role of JAK in RA Pathogenesis
- The Use of JAK Inhibitors in RA
- Key Takeaways/Conclusion
Term of Offering
This activity was released on May 31, 2017 and is valid for one year. Requests for credit must be made no later than June 1, 2018.
Global Contact Information: For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].
Instructions for Obtaining Credit: In order to receive credit, participants must complete the online evaluation and post-test at the end of this program. Participants must also score at least a 65% on the post-test. Statements of credit will be issued upon completion of the evaluation and post-test.
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v184.108.40.206 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader
MAC OS 10.2.8
Flash Player Plugin (v220.127.116.11 or greater)
Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh.
Fee Information & Refund/Cancellation Policy: There is no fee for this educational activity.
Disclosure of Conflicts of Interest: Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter: Roy Fleischmann, MD, MACR
Reported Financial Relationship: Consultant/Independent Contractor for: AbbVie, Lilly, Pfizer. Grant/Research Support from: AbbVie, Lilly, Pfizer
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Ashley Marostica, RN, MSN; Laura Gilsdorf; Ron Schaumburg; Mike LoPresti; Shirley Jones, MBA; and Scott Kober all have nothing to disclose.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Global Academy of Medical Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.